Lung Cancer Clinical Trials in Washington

Showing 81-100 of 170 trials

A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1

NCT02855125

This is a randomized, open-label, Phase 2 study of TAS-114 administered in combination with S-1, to investigate the efficacy, safety and tolerability of the TAS-114/S-1 regimen in patients with advanced or metastatic NSCLC. The study will be conducted internationally in 2 regions: Asian \[Japan\] and Western \[Europe and US\]. Patients will be randomized into TAS-114/S-1 arm versus S-1 control arm in a 1:1 ratio.

Advanced or Metastatic Non-small Cell Lung Cancer

Taiho Oncology, Inc.128 participantsStarted Aug 2016

Loma Linda, California, United States • Gainesville, Florida, United States • Cleveland, Ohio, United States +27 more locations

COMPLETED42 miles

DECIDE: Developing Tools for Lung Cancer Screening Discussion Improvement

NCT03891602

The purpose of this study is to learn about discussion between clinicians and their patients related to lung screening. Survey answers will be collected from both clinicians and their patients.

SmokingSmoking, TobaccoSmoking, Cigarette+1 more

Hackensack Meridian Health654 participantsStarted Mar 2019

Seattle, Washington, United States

A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1

DECIDE: Developing Tools for Lung Cancer Screening Discussion Improvement

Lung Cancer Trials in Other Cities

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

Tailoring Shared Decision Making for Lung Cancer Screening in Persons Living With HIV

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

Palliative Care Interventions for Outpatients Newly Diagnosed With Lung Cancer: Phase II

Milademetan in Advanced/Metastatic Solid Tumors

A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

Radiation in Stage I or Stage II Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC

Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

Other Conditions in Washington